sbph-10q_20200930.htm
false 2020 Q3 0001566373 --12-31 true true us-gaap:AccountingStandardsUpdate201813Member true Lesser of 10 years or the remaining term of the respective lease P1Y1M6D P1Y10M24D P5Y10M24D P5Y10M24D 0001566373 2020-01-01 2020-09-30 xbrli:shares 0001566373 2020-11-02 iso4217:USD 0001566373 2020-09-30 0001566373 2019-12-31 iso4217:USD xbrli:shares 0001566373 2020-07-01 2020-09-30 0001566373 2019-07-01 2019-09-30 0001566373 2019-01-01 2019-09-30 0001566373 us-gaap:CommonStockMember 2020-06-30 0001566373 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001566373 us-gaap:RetainedEarningsMember 2020-06-30 0001566373 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001566373 2020-06-30 0001566373 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001566373 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001566373 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001566373 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001566373 us-gaap:CommonStockMember 2020-09-30 0001566373 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001566373 us-gaap:RetainedEarningsMember 2020-09-30 0001566373 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001566373 us-gaap:CommonStockMember 2019-06-30 0001566373 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001566373 us-gaap:RetainedEarningsMember 2019-06-30 0001566373 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001566373 2019-06-30 0001566373 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001566373 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001566373 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001566373 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001566373 us-gaap:CommonStockMember 2019-09-30 0001566373 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001566373 us-gaap:RetainedEarningsMember 2019-09-30 0001566373 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001566373 2019-09-30 0001566373 us-gaap:CommonStockMember 2019-12-31 0001566373 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001566373 us-gaap:RetainedEarningsMember 2019-12-31 0001566373 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001566373 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001566373 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001566373 us-gaap:CommonStockMember sbph:AtTheMarketOfferingMember 2020-01-01 2020-09-30 0001566373 us-gaap:AdditionalPaidInCapitalMember sbph:AtTheMarketOfferingMember 2020-01-01 2020-09-30 0001566373 sbph:AtTheMarketOfferingMember 2020-01-01 2020-09-30 0001566373 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0001566373 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001566373 us-gaap:CommonStockMember 2018-12-31 0001566373 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001566373 us-gaap:RetainedEarningsMember 2018-12-31 0001566373 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001566373 2018-12-31 0001566373 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001566373 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001566373 us-gaap:CommonStockMember sbph:AtTheMarketOfferingMember 2019-01-01 2019-09-30 0001566373 us-gaap:AdditionalPaidInCapitalMember sbph:AtTheMarketOfferingMember 2019-01-01 2019-09-30 0001566373 sbph:AtTheMarketOfferingMember 2019-01-01 2019-09-30 0001566373 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0001566373 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 sbph:Subsidiary 0001566373 us-gaap:ConvertibleDebtMember sbph:PrepaymentNoticeAndPayOffLetterMember 2020-04-08 2020-04-08 0001566373 us-gaap:MoneyMarketFundsMember 2020-09-30 0001566373 us-gaap:MoneyMarketFundsMember 2019-12-31 0001566373 us-gaap:USTreasurySecuritiesMember 2019-12-31 0001566373 us-gaap:EquipmentMember srt:MinimumMember 2020-01-01 2020-09-30 0001566373 us-gaap:EquipmentMember srt:MaximumMember 2020-01-01 2020-09-30 0001566373 us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-09-30 0001566373 us-gaap:LeaseholdImprovementsMember 2020-01-01 2020-09-30 sbph:Segment 0001566373 us-gaap:ConvertibleDebtSecuritiesMember 2019-01-01 2019-09-30 0001566373 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001566373 us-gaap:WarrantMember 2019-01-01 2019-09-30 0001566373 sbph:StockOptionsAndInducementAwardsMember 2020-01-01 2020-09-30 0001566373 sbph:StockOptionsAndInducementAwardsMember 2019-01-01 2019-09-30 0001566373 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001566373 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001566373 us-gaap:ConvertibleDebtSecuritiesMember 2019-07-01 2019-09-30 0001566373 us-gaap:WarrantMember 2020-07-01 2020-09-30 0001566373 us-gaap:WarrantMember 2019-07-01 2019-09-30 0001566373 sbph:StockOptionsAndInducementAwardsMember 2020-07-01 2020-09-30 0001566373 sbph:StockOptionsAndInducementAwardsMember 2019-07-01 2019-09-30 0001566373 us-gaap:RestrictedStockUnitsRSUMember 2020-07-01 2020-09-30 0001566373 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0001566373 sbph:MarketableSecuritiesCurrentMember us-gaap:USTreasurySecuritiesMember 2020-09-30 0001566373 sbph:MarketableSecuritiesCurrentMember 2020-09-30 0001566373 sbph:MarketableSecuritiesCurrentMember us-gaap:CorporateBondSecuritiesMember 2019-12-31 0001566373 sbph:MarketableSecuritiesCurrentMember us-gaap:USTreasurySecuritiesMember 2019-12-31 0001566373 sbph:MarketableSecuritiesCurrentMember 2019-12-31 0001566373 us-gaap:EquipmentMember 2020-09-30 0001566373 us-gaap:EquipmentMember 2019-12-31 0001566373 us-gaap:FurnitureAndFixturesMember 2020-09-30 0001566373 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001566373 us-gaap:LeaseholdImprovementsMember 2020-09-30 0001566373 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001566373 us-gaap:MoneyMarketFundsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-09-30 0001566373 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-09-30 0001566373 us-gaap:USTreasurySecuritiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-09-30 0001566373 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0001566373 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-09-30 0001566373 us-gaap:FairValueInputsLevel1Member 2020-09-30 0001566373 us-gaap:FairValueInputsLevel2Member 2020-09-30 0001566373 us-gaap:CarryingReportedAmountFairValueDisclosureMember sbph:WarrantLiabilitiesMember 2020-09-30 0001566373 sbph:WarrantLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2020-09-30 0001566373 us-gaap:FairValueInputsLevel3Member 2020-09-30 0001566373 us-gaap:MoneyMarketFundsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0001566373 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001566373 us-gaap:USTreasurySecuritiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0001566373 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001566373 us-gaap:FixedIncomeSecuritiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0001566373 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001566373 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0001566373 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001566373 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001566373 us-gaap:CarryingReportedAmountFairValueDisclosureMember sbph:WarrantLiabilitiesMember 2019-12-31 0001566373 sbph:WarrantLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001566373 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001566373 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2018-12-31 0001566373 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2019-01-01 2019-12-31 0001566373 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2019-12-31 0001566373 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2020-01-01 2020-09-30 0001566373 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2020-09-30 0001566373 us-gaap:IPOMember 2016-05-31 0001566373 us-gaap:IPOMember 2016-06-30 0001566373 us-gaap:IPOMember 2020-09-30 0001566373 us-gaap:IPOMember 2020-01-01 2020-09-30 0001566373 sbph:MayTwoThousandAndSixteenIPOWarrantsMember 2016-05-01 2016-05-31 xbrli:pure 0001566373 sbph:JuneTwoThousandAndSixteenIPOWarrantsMember 2016-06-01 2016-06-30 0001566373 us-gaap:PrivatePlacementMember 2016-11-01 2016-11-30 0001566373 us-gaap:PrivatePlacementMember 2016-11-30 0001566373 us-gaap:PrivatePlacementMember us-gaap:WarrantMember 2016-11-30 0001566373 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-09-30 0001566373 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001566373 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedTermMember 2020-09-30 0001566373 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001566373 us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2020-09-30 0001566373 us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001566373 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-09-30 0001566373 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-12-31 0001566373 us-gaap:ConvertibleDebtMember 2019-09-19 0001566373 us-gaap:WarrantMember srt:AffiliatedEntityMember 2019-09-30 0001566373 us-gaap:WarrantMember srt:AffiliatedEntityMember 2019-09-01 2019-09-30 0001566373 us-gaap:WarrantMember srt:AffiliatedEntityMember 2020-04-08 0001566373 us-gaap:WarrantMember srt:AffiliatedEntityMember 2020-01-01 2020-09-30 0001566373 sbph:SeptemberTwoThousandAndNineteenWarrantsMember 2019-09-30 0001566373 sbph:SeptemberTwoThousandAndNineteenWarrantsMember 2019-09-01 2019-09-30 0001566373 sbph:SeptemberTwoThousandAndNineteenWarrantsMember 2020-01-01 2020-09-30 0001566373 sbph:SeptemberTwoThousandAndNineteenWarrantsMember 2019-01-01 2019-12-31 0001566373 us-gaap:WarrantMember 2018-12-31 0001566373 us-gaap:WarrantMember 2019-01-01 2019-12-31 0001566373 us-gaap:WarrantMember 2019-12-31 0001566373 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001566373 us-gaap:WarrantMember 2020-09-30 0001566373 sbph:SalesAgreementMember sbph:CantorFitzgeraldAndCompanyMember srt:MaximumMember 2017-08-31 0001566373 sbph:SalesAgreementMember sbph:CantorFitzgeraldAndCompanyMember 2017-08-31 0001566373 sbph:SalesAgreementMember sbph:CantorFitzgeraldAndCompanyMember 2020-07-01 2020-09-30 0001566373 sbph:SalesAgreementMember sbph:CantorFitzgeraldAndCompanyMember 2020-01-01 2020-09-30 0001566373 sbph:SalesAgreementMember sbph:CantorFitzgeraldAndCompanyMember 2019-07-01 2019-09-30 0001566373 sbph:SalesAgreementMember sbph:CantorFitzgeraldAndCompanyMember 2019-01-01 2019-09-30 0001566373 sbph:TwoThousandAndFourteenStockIncentivePlanMember 2014-04-30 0001566373 sbph:TwoThousandAndFifteenStockIncentivePlanMember srt:MaximumMember 2016-05-11 0001566373 sbph:TwoThousandAndFourteenStockIncentivePlanMember 2016-05-11 0001566373 sbph:TwoThousandAndFifteenStockIncentivePlanMember 2018-03-01 2018-03-31 0001566373 sbph:TwoThousandAndFifteenStockIncentivePlanMember 2020-01-01 2020-09-30 0001566373 sbph:TwoThousandAndFifteenStockIncentivePlanMember 2018-03-31 0001566373 sbph:TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlansMember 2020-09-30 0001566373 sbph:TwoThousandAndFifteenStockIncentivePlanMember 2016-05-10 2016-05-11 0001566373 sbph:TwoThousandAndFifteenStockIncentivePlanMember 2020-09-30 0001566373 2015-01-01 2015-12-31 0001566373 sbph:TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlansMember 2018-12-31 0001566373 sbph:TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlansMember 2019-01-01 2019-12-31 0001566373 sbph:TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlansMember 2019-12-31 0001566373 sbph:TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlansMember 2020-01-01 2020-09-30 0001566373 sbph:TwoThousandAndFourteenStockIncentivePlanMember 2020-01-01 2020-09-30 0001566373 sbph:TwoThousandAndFourteenStockIncentivePlanMember us-gaap:CommonStockMember 2020-09-30 0001566373 sbph:TwoThousandAndFourteenStockIncentivePlanMember us-gaap:CommonStockMember 2019-12-31 0001566373 sbph:TwoThousandEighteenNewHireInducementStockOptionAwardMember 2018-01-01 2018-01-31 0001566373 sbph:TwoThousandEighteenNewHireInducementStockOptionAwardMember 2018-01-31 0001566373 sbph:TwoThousandNineteenNewHireInducementStockOptionAwardMember 2019-02-01 2019-02-28 0001566373 sbph:TwoThousandNineteenNewHireInducementStockOptionAwardMember 2019-02-28 0001566373 sbph:PerformanceBasedRestrictedStockUnitsMember 2020-01-01 2020-09-30 0001566373 sbph:PerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-01-01 2019-01-31 0001566373 sbph:PerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-01-01 2019-01-31 0001566373 sbph:PerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2019-01-01 2019-01-31 0001566373 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0001566373 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001566373 us-gaap:RestrictedStockUnitsRSUMember 2019-09-30 0001566373 sbph:PerformanceBasedRestrictedStockUnitsMember 2020-03-01 2020-03-31 0001566373 sbph:PerformanceBasedRestrictedStockUnitsMember sbph:SeniorManagementMember 2020-04-01 2020-04-30 0001566373 sbph:PerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember sbph:SeniorManagementMember 2020-04-01 2020-04-30 0001566373 sbph:PerformanceBasedRestrictedStockUnitsMember sbph:ShareBasedPaymentArrangementTrancheFiveMember sbph:SeniorManagementMember 2020-04-01 2020-04-30 0001566373 sbph:PerformanceBasedRestrictedStockUnitsMember sbph:ShareBasedPaymentArrangementTrancheFiveMember sbph:SeniorManagementMember 2020-07-01 2020-09-30 0001566373 sbph:PerformanceBasedRestrictedStockUnitsMember sbph:ShareBasedPaymentArrangementTrancheFiveMember sbph:SeniorManagementMember 2020-01-01 2020-09-30 0001566373 sbph:TimeBasedRestrictedStockUnitsMember 2020-01-01 2020-09-30 0001566373 sbph:TimeBasedRestrictedStockUnitsMember 2020-07-01 2020-09-30 0001566373 sbph:ShareBasedPaymentArrangementTrancheFourMember sbph:TimeBasedRestrictedStockUnitsMember 2020-01-01 2020-09-30 0001566373 sbph:ShareBasedPaymentArrangementTrancheFiveMember sbph:TimeBasedRestrictedStockUnitsMember 2020-01-01 2020-09-30 0001566373 sbph:TimeBasedRestrictedStockUnitsMember 2020-03-01 2020-03-31 0001566373 sbph:PerformanceBasedRestrictedStockUnitsMember 2019-12-31 0001566373 sbph:PerformanceBasedRestrictedStockUnitsMember 2020-09-30 0001566373 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember sbph:TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlansMember 2020-07-01 2020-09-30 0001566373 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember sbph:TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlansMember 2019-07-01 2019-09-30 0001566373 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember sbph:TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlansMember 2020-01-01 2020-09-30 0001566373 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember sbph:TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlansMember 2019-01-01 2019-09-30 0001566373 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember sbph:TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlansMember 2020-07-01 2020-09-30 0001566373 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember sbph:TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlansMember 2019-07-01 2019-09-30 0001566373 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember sbph:TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlansMember 2020-01-01 2020-09-30 0001566373 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember sbph:TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlansMember 2019-01-01 2019-09-30 0001566373 us-gaap:EmployeeStockOptionMember sbph:TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlansMember 2020-07-01 2020-09-30 0001566373 us-gaap:EmployeeStockOptionMember sbph:TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlansMember 2019-07-01 2019-09-30 0001566373 us-gaap:EmployeeStockOptionMember sbph:TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlansMember 2020-01-01 2020-09-30 0001566373 us-gaap:EmployeeStockOptionMember sbph:TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlansMember 2019-01-01 2019-09-30 0001566373 sbph:TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlansMember sbph:TimeBasedRestrictedStockUnitsMember 2020-09-30 0001566373 sbph:TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlansMember sbph:TimeBasedRestrictedStockUnitsMember 2020-01-01 2020-09-30 0001566373 us-gaap:IPOMember 2019-12-31 0001566373 sbph:PrivatePlacementWarrantsMember 2020-09-30 0001566373 sbph:PrivatePlacementWarrantsMember 2019-12-31 0001566373 sbph:ConvertibleTermLoanMember 2019-12-31 0001566373 sbph:PontifaxWarrantsMember 2020-09-30 0001566373 sbph:PontifaxWarrantsMember 2019-12-31 0001566373 sbph:SeptemberTwoThousandAndNineteenWarrantsMember 2020-09-30 0001566373 sbph:SeptemberTwoThousandAndNineteenWarrantsMember 2019-12-31 0001566373 sbph:TwoThousandAndFifteenStockIncentivePlanMember 2019-12-31 0001566373 sbph:TwoThousandEighteenNewHireInducementStockOptionAwardMember 2020-09-30 0001566373 sbph:TwoThousandEighteenNewHireInducementStockOptionAwardMember 2019-12-31 0001566373 us-gaap:ConvertibleDebtMember 2019-09-30 0001566373 us-gaap:ConvertibleDebtMember 2020-01-01 2020-09-30 0001566373 us-gaap:ConvertibleDebtMember 2020-09-30 0001566373 us-gaap:ConvertibleDebtMember srt:AffiliatedEntityMember 2020-09-30 0001566373 us-gaap:ConvertibleDebtMember sbph:PrepaymentNoticeAndPayOffLetterMember 2020-09-30 0001566373 us-gaap:ConvertibleDebtMember srt:AffiliatedEntityMember sbph:PrepaymentNoticeAndPayOffLetterMember 2020-09-30 0001566373 us-gaap:ConvertibleDebtMember srt:AffiliatedEntityMember sbph:PrepaymentNoticeAndPayOffLetterMember 2020-01-01 2020-09-30 0001566373 srt:AffiliatedEntityMember us-gaap:WarrantMember 2020-09-30 0001566373 us-gaap:ConvertibleDebtMember 2020-07-01 2020-09-30 0001566373 us-gaap:ConvertibleDebtMember 2019-07-01 2019-09-30 0001566373 us-gaap:ConvertibleDebtMember 2019-01-01 2019-09-30 0001566373 sbph:PrincipalOfficeAndLaboratorySpaceMember 2020-09-30 0001566373 sbph:FormerHeadquartersMember 2020-09-30 0001566373 sbph:PrincipalOfficeAndLaboratorySpaceMember 2020-01-01 2020-09-30

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission File Number: 001-37718

 

Spring Bank Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

52-2386345

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

 

35 Parkwood Drive, Suite 210

Hopkinton, MA

01748

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (508473-5993

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Trading

Symbol

 

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

SBPH

 

The Nasdaq Stock Market, LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

 

 

 

 

Non-accelerated filer

☐  

Smaller reporting company

 

 

 

 

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

As of November 2, 2020, the registrant had 17,267,202 shares of common stock, $0.0001 par value per share, outstanding.

 

 

 


 

Spring Bank Pharmaceuticals, Inc.

 

INDEX

 

 

 

 

 

PART I. FINANCIAL INFORMATION

Page    

 

Item 1.

Consolidated Financial Statements (Unaudited)

 

 

Consolidated Balance Sheets

3

 

Consolidated Statements of Operations and Comprehensive Loss

4

 

Consolidated Statements of Stockholders’ Equity

5

 

Consolidated Statements of Cash Flows

7

 

Notes to Unaudited Consolidated Financial Statements

8

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

23

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

33

Item 4.

Controls and Procedures

33

 

 

PART II. OTHER INFORMATION

 

Item 1.

Legal Proceedings

35

Item 1A.

Risk Factors

35

Item 6.

Exhibits

36

Exhibit Index

37

Signatures

38

 

 

 

i


 

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “design,” “expect,” “seek,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions.

These forward-looking statements include, but are not limited to, statements about:

 

our proposed combination with F-star Therapeutics Limited (“F-star”);

 

our ongoing and planned preclinical studies and clinical trials;

 

preclinical study data and clinical trial data and the timing of results of our ongoing clinical studies and/or trials; and

 

our estimates regarding prospects, strategies, expenses, operating capital requirements, results of operations and needs for additional financing.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Factors that could cause actual results or events to differ materially from the forward-looking statements that we make include, but are not limited to, the following:

Our proposed business combination with F-star is subject to a number of closing conditions, including a condition requiring our stockholders to approve the issuance of Spring Bank common stock at the closing of the proposed combination, and it may never occur. Even if this proposed combination is completed, the number of shares of our common stock to be issued to the holders of share capital of F-star will be based on an exchange ratio formula that is subject to adjustment based on, among other things, the amount of our net cash upon the closing of the business combination and the amount of proceeds from a concurrent private placement conducted by F-star. This exchange ratio is not adjustable based on the value of our shares of common stock or on the value of the share capital of F-star. The proposed combination also contemplates that our stockholders as of a date prior to the closing of the business combination will receive two separate contingent value rights related to our STING programs. There can be no assurance that our stockholders will ever receive payment pursuant to these rights, and these rights may expire valueless.

We are very early in our development efforts and our product candidates may not be successful in later stage clinical trials. Results obtained in our preclinical studies and clinical trials to date are not necessarily indicative of results to be obtained in future clinical trials. As a result, our product candidates may never be approved as marketable therapeutics.

We rely, and expect to continue to rely, on third parties to conduct our clinical trials and to manufacture our product candidates for preclinical and clinical testing. These third parties may not perform satisfactorily, which could delay our product development activities.

If we are unable to adequately protect our proprietary technology or obtain and maintain issued patents which are sufficient to protect our product candidates, others could compete against us more directly, which would have a material adverse impact on our business, results of operations, financial condition and prospects.

Business interruptions resulting from the coronavirus disease 2019 (COVID-19) outbreak or similar public health crises could cause a disruption of the development of our product candidates and adversely impact our business.

You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. You should also read carefully the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2019, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, as filed with the Securities and Exchange Commission on February 14, 2020, May 7, 2020 and August 10, 2020, respectively, to better understand the risks and uncertainties inherent in our business and underlying any forward-looking statements. You are advised, however, to consult any further disclosures we make on related subjects in our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, press releases, and our website. Any forward-looking statements that we make in this Quarterly Report on Form 10-Q speak only as of the date of this Quarterly Report on Form 10-Q, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events.

2


 

PART I—FINANCIAL INFORMATION

Item 1.

Financial Statements.

SPRING BANK PHARMACEUTICALS, INC.

CONSOLIDATED BALANCE SHEETS

(In Thousands, Except Share and Per Share Data)

 

 

 

September 30,

 

 

December 31,

 

 

 

2020

 

 

2019

 

ASSETS

 

(unaudited)

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

     Cash and cash equivalents

 

$

9,988

 

 

$

28,709

 

     Marketable securities

 

 

9,993

 

 

 

25,746

 

     Prepaid expenses and other current assets

 

 

2,599

 

 

 

3,522

 

Total current assets

 

 

22,580

 

 

 

57,977

 

     Property and equipment, net

 

 

1,926

 

 

 

2,234

 

     Operating lease right-of-use assets

 

 

2,504

 

 

 

2,717

 

     Restricted cash

 

 

 

 

 

234

 

     Other assets

 

 

234

 

 

 

35

 

Total

 

$

27,244

 

 

$

63,197

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

     Accounts payable

 

$

3,135

 

 

$

2,210

 

     Accrued expenses and other current liabilities

 

 

2,777

 

 

 

2,438

 

     Accrued interest payable

 

 

 

 

 

403

 

     Operating lease liabilities, current

 

 

333

 

 

 

355

 

Total current liabilities

 

 

6,245

 

 

 

5,406

 

     Convertible term loan, net of unamortized discount

 

 

 

 

 

19,070

 

     Warrant liabilities

 

 

56

 

 

 

299

 

     Operating lease liabilities, noncurrent

 

 

2,629

 

 

 

2,869

 

     Other long-term liabilities

 

 

 

 

 

27

 

Total liabilities

 

 

8,930

 

 

 

27,671

 

Commitments and contingencies (Note 11)

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 par value—authorized, 10,000,000 shares at September 30,

     2020 and December 31, 2019; no shares issued or outstanding at September 30,

     2020 and December 31, 2019

 

 

 

 

 

 

Common stock, $0.0001 par value—authorized, 200,000,000 shares at September 30,

     2020 and December 31, 2019; 17,267,202 and 16,513,763 shares issued and

     outstanding at September 30, 2020 and December 31, 2019, respectively

 

 

2

 

 

 

2

 

Additional paid-in capital

 

 

164,562

 

 

 

161,924

 

Accumulated deficit

 

 

(146,245

)

 

 

(126,165

)

Accumulated other comprehensive loss

 

 

(5

)

 

 

(235

)

Total stockholders’ equity

 

 

18,314

 

 

 

35,526

 

Total

 

$

27,244

 

 

$

63,197

 

 

See accompanying notes to consolidated financial statements.

 

 

3


 

SPRING BANK PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In Thousands, Except Share and Per Share Data)

 

 

 

For the Three Months Ended September 30,

 

 

For the Nine Months Ended September 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

2,516

 

 

$

5,228

 

 

$

11,023

 

 

$

18,070

 

General and administrative

 

 

2,832

 

 

 

2,247

 

 

 

7,875

 

 

 

7,547

 

Total operating expenses

 

 

5,348

 

 

 

7,475

 

 

 

18,898

 

 

 

25,617

 

Loss from operations

 

 

(5,348

)

 

 

(7,475

)

 

 

(18,898

)

 

 

(25,617

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

8

 

 

 

271

 

 

 

293

 

 

 

957

 

Interest expense

 

 

 

 

 

(63

)

 

 

(511

)

 

 

(63

)

Loss on extinguishment of convertible term loan

 

 

 

 

 

 

 

 

(1,207

)

 

 

 

Change in fair value of warrant liabilities

 

 

(18

)

 

 

355

 

 

 

243

 

 

 

8,061

 

Net loss

 

 

(5,358

)

 

 

(6,912

)

 

 

(20,080

)

 

 

(16,662

)

Unrealized gain/(loss) on marketable securities

 

 

(4

)

 

 

(20

)

 

 

230

 

 

 

(233

)

Comprehensive loss

 

$

(5,362

)

 

$

(6,932

)

 

$

(19,850

)

 

$

(16,895

)

Net loss per common share - basic and diluted

 

$

(0.31

)

 

$

(0.42

)

 

$

(1.19

)

 

$

(1.01

)

Weighted-average number of shares outstanding - basic and diluted

 

 

17,248,545

 

 

 

16,459,155

 

 

 

16,942,582

 

 

 

16,446,582

 

 

See accompanying notes to consolidated financial statements.

 

 

 


4


 

SPRING BANK PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2020 AND 2019

(In Thousands, Except Share and Per Share Data)

 

For the Three Months Ended

 

Common Stock

 

 

Additional

Paid-in

 

 

Accumulated

 

 

Other

Comprehensive

 

 

Total

Stockholders’

 

September 30, 2020

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Income (Loss)

 

 

Equity

 

Balance at June 30, 2020

 

 

17,248,545

 

 

$

2

 

 

$

164,118

 

 

$

(140,887

)

 

$

(1

)

 

$

23,232

 

Stock-based compensation

 

 

 

 

 

 

 

 

419

 

 

 

 

 

 

 

 

 

419

 

Issuance of common stock for services rendered

 

 

18,657

 

 

 

 

 

 

25

 

 

 

 

 

 

 

 

 

25

 

Net unrealized gain on marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(4

)

 

 

(4

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

(5,358

)

 

 

 

 

 

(5,358

)

Balance at September 30, 2020

 

 

17,267,202

 

 

$

2

 

 

$

164,562

 

 

$

(146,245

)

 

$

(5

)

 

$

18,314

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended

 

Common Stock

 

 

Additional

Paid-in

 

 

Accumulated

 

 

Other

Comprehensive

 

 

Total

Stockholders’

 

September 30, 2019

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Income (Loss)

 

 

Equity

 

Balance at June 30, 2019

 

 

16,459,155

 

 

$

2

 

 

$

159,975

 

 

$

(111,818

)

 

$

(218

)

 

$

47,941

 

Stock-based compensation

 

 

 

 

 

 

 

 

752

 

 

 

 

 

 

 

 

 

752

 

Issuance of common stock for services rendered

 

 

17,187

 

 

 

 

 

 

59

 

 

 

 

 

 

 

 

 

59

 

Issuance of warrants in connection with term loan

 

 

 

 

 

 

 

 

552

 

 

 

 

 

 

 

 

 

552

 

Issuance of warrants to a service provider

 

 

 

 

 

 

 

 

19

 

 

 

 

 

 

 

 

 

19

 

Offering costs in connection with common stock

     offering

 

 

 

 

 

 

 

 

25

 

 

 

 

 

 

 

 

 

25

 

Net unrealized loss on marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(20

)

 

 

(20

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

(6,912

)

 

 

 

 

 

(6,912

)

Balance at September 30, 2019

 

 

16,476,342

 

 

$

2

 

 

$

161,382

 

 

$

(118,730

)

 

$

(238

)

 

$

42,416

 

 

See accompanying notes to consolidated financial statements.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5


 

SPRING BANK PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2020 AND 2019

(In Thousands, Except Share and Per Share Data)

 

For the Nine Months Ended

 

Common Stock

 

 

Additional

Paid-in

 

 

Accumulated

 

 

Other

Comprehensive

 

 

Total

Stockholders’

 

September 30, 2020

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Income (Loss)

 

 

Equity

 

Balance at December 31, 2019

 

 

16,513,763

 

 

$

2

 

 

$

161,924

 

 

$

(126,165

)

 

$

(235

)

 

$

35,526

 

Stock-based compensation

 

 

 

 

 

 

 

 

1,660

 

 

 

 

 

 

 

 

 

1,660

 

Issuance of common stock for services rendered

 

 

62,544

 

 

 

 

 

 

75

 

 

 

 

 

 

 

 

 

75

 

Issuance of common stock in connection with

     at-the-market offering, net of issuance costs

 

 

690,895

 

 

 

 

 

 

849

 

 

 

 

 

 

 

 

 

849

 

Convertible term loan warrant amendment

 

 

 

 

 

 

 

 

 

54

 

 

 

 

 

 

 

 

 

54

 

Net unrealized gain on marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

230

 

 

 

230

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(20,080

)

 

 

 

 

 

(20,080

)

Balance at September 30, 2020

 

 

17,267,202

 

 

$

2

 

 

$

164,562

 

 

$

(146,245

)

 

$

(5

)

 

$

18,314

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the Nine Months Ended

 

Common Stock

 

 

Additional

Paid-in

 

 

Accumulated

 

 

Other

Comprehensive

 

 

Total

Stockholders’

 

September 30, 2019

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Income (Loss)

 

 

Equity

 

Balance at December 31, 2018

 

 

16,434,614

 

 

$

2

 

 

$

157,931

 

 

$

(102,068

)

 

$

(5

)

 

$

55,860

 

Stock-based compensation

 

 

 

 

 

 

 

 

2,647

 

 

 

 

 

 

 

 

 

2,647

 

Issuance of common stock for services rendered

 

 

41,128

 

 

 

 

 

 

202

 

 

 

 

 

 

 

 

 

202

 

Issuance of common stock in connection with

     at-the-market offering, net of issuance costs

 

 

600

 

 

 

 

 

 

6

 

 

 

 

 

 

 

 

 

6

 

Issuance of warrants in connection with term loan

 

 

 

 

 

 

 

 

552

 

 

 

 

 

 

 

 

 

552

 

Issuance of warrants to a service provider

 

 

 

 

 

 

 

 

19

 

 

 

 

 

 

 

 

 

19

 

Offering costs in connection with common stock

     offering

 

 

 

 

 

 

 

 

25

 

 

 

 

 

 

 

 

 

25

 

Net unrealized loss on marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(233

)

 

 

(233

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

(16,662

)

 

 

 

 

 

(16,662

)

Balance at September 30, 2019

 

 

16,476,342

 

 

$

2

 

 

$

161,382

 

 

$

(118,730

)

 

$

(238

)

 

$

42,416

 

 

See accompanying notes to consolidated financial statements.

 

 

6


 

SPRING BANK PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In Thousands)

 

 

 

For the Nine Months Ended

September 30,

 

 

 

2020

 

 

2019

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(20,080

)

 

$

(16,662

)

Adjustments for:

 

 

 

 

 

 

 

 

Depreciation

 

 

287

 

 

 

263

 

Loss on the disposal of property and equipment

 

 

25

 

 

 

 

Operating lease right-of-use asset amortization

 

 

213

 

 

 

196

 

Change in fair value of warrant liabilities

 

 

(243

)

 

 

(8,061

)

Loss on extinguishment of convertible term loan

 

 

1,207

 

 

 

 

Non-cash interest expense

 

 

77

 

 

 

10

 

Non-cash investment expense

 

 

(247

)

 

 

(60

)

Non-cash stock-based compensation

 

 

1,735

 

 

 

2,825

 

Non-cash issuance of warrants to a service provider

 

 

 

 

 

19

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

 

923

 

 

 

(78

)

Other assets

 

 

(199

)

 

 

132

 

Accounts payable

 

 

925

 

 

 

1,106

 

Accrued expenses and other liabilities

 

 

(91

)

 

 

(82

)

Operating lease liabilities

 

 

(262

)

 

 

(79

)

Net cash used in operating activities

 

 

(15,730

)

 

 

(20,471

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Proceeds from sale of marketable securities

 

 

37,230

 

 

 

26,767

 

Purchases of marketable securities

 

 

(21,000

)

 

 

(6,000

)

Purchases of property and equipment

 

 

(4

)

 

 

(208

)

Net cash provided by investing activities

 

 

16,226

 

 

 

20,559

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Payment of convertible term loan and prepayment fee

 

 

(20,300

)

 

 

 

Proceeds from term loan and warrants

 

 

 

 

 

20,000

 

Issuance costs in connection with term loan and warrants

 

 

 

 

 

(447

)

Proceeds from issuance of common stock in connection

     with at-the-market offering, net of issuance costs